ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,347.19
-0.28%
Dow Jones
39,448.08
-0.56%
Gold vs US Dollar
2,350.66
-1.31%
Brent Oil
82.00
0.58%
Bitcoin
67,743.30
-1.97%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tourmaline Bio Inc (TRML)

  7. Tourmaline Bio Inc (TRML) News

Tourmaline Bio (TRML)

Tourmaline Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TRML
DateTimeSourceHeadlineSymbolCompany
23/05/202412:10GlobeNewswire Inc.Tourmaline Bio to Present at the Jefferies Global Healthcare ConferenceNASDAQ:TRMLTourmaline Bio Inc
16/05/202412:00GlobeNewswire Inc.Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY TrialNASDAQ:TRMLTourmaline Bio Inc
13/05/202421:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TRMLTourmaline Bio Inc
13/05/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
13/05/202412:00GlobeNewswire Inc.Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:TRMLTourmaline Bio Inc
02/04/202412:00GlobeNewswire Inc.Avalo Therapeutics Appoints Biotech Leaders to Board of DirectorsNASDAQ:TRMLTourmaline Bio Inc
19/03/202411:00GlobeNewswire Inc.Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:TRMLTourmaline Bio Inc
27/02/202412:30GlobeNewswire Inc.Tourmaline Bio to Present at Upcoming Investor ConferencesNASDAQ:TRMLTourmaline Bio Inc
15/02/202402:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TRMLTourmaline Bio Inc
15/02/202401:51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TRMLTourmaline Bio Inc
09/02/202421:22Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TRMLTourmaline Bio Inc
01/02/202413:00GlobeNewswire Inc.Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:TRMLTourmaline Bio Inc
29/01/202421:01GlobeNewswire Inc.Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:TRMLTourmaline Bio Inc
26/01/202421:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
26/01/202421:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TRMLTourmaline Bio Inc
25/01/202412:00GlobeNewswire Inc.Tourmaline Bio Announces Pricing of Public Offering of Common StockNASDAQ:TRMLTourmaline Bio Inc
25/01/202402:20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TRMLTourmaline Bio Inc
24/01/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
24/01/202421:05GlobeNewswire Inc.Tourmaline Bio Announces Proposed Public Offering of Common StockNASDAQ:TRMLTourmaline Bio Inc
08/01/202414:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
08/01/202412:00GlobeNewswire Inc.Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)NASDAQ:TRMLTourmaline Bio Inc
15/12/202321:00GlobeNewswire Inc.Tourmaline Bio added to the NASDAQ Biotechnology IndexNASDAQ:TRMLTourmaline Bio Inc
14/12/202313:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
14/12/202312:30GlobeNewswire Inc.Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the BoardNASDAQ:TRMLTourmaline Bio Inc
30/11/202313:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
01/11/202312:00GlobeNewswire Inc.Tourmaline Bio to Present at Upcoming Investor ConferencesNASDAQ:TRMLTourmaline Bio Inc
24/10/202301:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
24/10/202301:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
24/10/202301:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
24/10/202301:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
 Showing the most relevant articles for your search:NASDAQ:TRML

Your Recent History

TSXV
URC.WT
Uranium Royalty
LSE
QV13
Mor.st.fin 26
BIT
P1ZD65
NLBNPIT1ZD65 20240920 900
ZBCM
DOGEBTC
Dogecoin
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved